To examine the defect in side-chain oxidation during the formation of bile acids in cerebrotendinous xanthomatosis, we measured in vitro hepatic microsomal hydroxylations at C-12 and C-25 and mitochondrial hydroxylation at C-26 and related them to the pool size and synthesis rates of cholic acid and chenodeoxycholic acid as determined by the isotope dilution technique. Hepatic microsomes and mitochondria were prepared from seven subjects with cerebrotendinous xanthomatosis and five controls. Primary bile acid synthesis was markedly reduced in cerebrotendinous xanthomatosis as follows: cholic acid, 133 +/-30 vs. 260 +/-60 mg/d in controls; and chenodeoxycholic acid, 22 +/-10 vs. 150 +/-30 mg/d in controls. As postulated for chenodeoxycholic acid synthesis, mitochondrial 26-hydroxylation of 5 beta-cholestane-3 alpha, 7 alpha-diol was present in all specimens and was 30-fold more active than the corresponding microsomal 25-hydroxylation. However, mean mitochondrial 26-hydroxylation of 5 beta-cholestane-3 alpha,7 alpha-diol was less active in cerebrotendinous xanthomatosis than in controls: 59 +/-17 compared with 126 +/-21 pmol/mg protein per min. As for cholic acid synthesis, microsomal 25-hydroxylation of 5 beta-cholestane-3 alpha,7 alpha,12 alpha-triol was substantially higher in cerebrotendinous xanthomatosis and control preparations (620 +/-103 and 515 +/-64 pmol/mg protein per min, respectively) than the corresponding control mitochondrial 26-hydroxylation of the same substrate (165 +/-25 pmol/mg protein per min 
Introduction
Cholic acid' and chenodeoxycholic acid are primary bile acids produced in the liver of humans and most mammals. Both bile acids are similar in structure, differing only in the number of ring hydroxyl groups. Although arising from the same precursor, cholesterol (I) (see Fig. 1 ), and sharing several early formative steps, their respective synthetic pathways diverge after the introduction of the 12a-hydroxyl group into 7a-hydroxy-4-cholesten-3-one (III) to form 7a, 12a-dihydroxy-4-cholesten-3-one (VIII) (1) . The latter precursor is totally committed to cholic acid synthesis. Accordingly, the enzyme that catalyzes 12a-hydroxylation (7a-hydroxy-4-cholesten-3-one12a-hydroxylase) may control, in part, the relative proportions of cholic acid and chenodeoxycholic acid that are found in the enterohepatic pool.
Recently, defective bile acid metabolism has been discovered in the rare inherited lipid storage disease, cerebrotendinous xanthomatosis (CTX9 (2) . The abnormalities include a marked deficiency of chenodeoxycholic acid in the bile and the excretion of large quantities of bile alcohols that contained 27 carbons in the bile, urine, and feces (3) (4) (5) (6) (7) . Virtually all of these bile alcohols are hydroxylated at C-12 and C-25 and when excreted in urine and bile are conjugated at C-3 with glucuronic acid (6, 7) . Total bile acid synthesis as measured by the sterol balance method was reduced 50% (8) . Although the exact enzymatic defect in bile acid synthesis in CTX has not been defined completely, the major biochemical abnormality apparently involves the incomplete oxidation of the cholesterol side chain (4) . The accumulation of C27 bile alcohols that are 12a-hydroxylated suggests that cholic acid synthesis is impaired, while the deficiency of chenodeoxycholic acid in the bile points to reduced formation of this primary bile acid. Recently, Oftebro and co-workers (9, 10) have reported that hepatic mitochondrial 26-hydroxylase activity, the putative initial reaction for side-chain oxidation in both cholic and chenodeoxycholic acid synthesis, was completely absent from the liver 1 . The following common names have been substituted for the systematic names in this paper. cholesterol, 5-cholesten-3#-ol; cholestanol, 5a-cholestan-3#-ol; cholic acid, 3a,7a,l2a-trihydroxy-5S-cholan-24-oic acid; chenodeoxycholic acid, 3a,7a-dihydroxy-5(-cholan-24-oic acid; deoxycholic acid, 3a, 12a-dihydroxy-5#-cholan-24-oic acid; lithocholic acid, 3a-hydroxy-5#-cholan-24-oic acid. of a single CTX subject. This enzyme catalyzes the conversion of 5f3-cholestane-3a,7a,12a-triol (IX) and 513-cholestane-3a,7a-diol (IV) into 5/3-cholestane-3a,7a, 12a,26-tetrol (XI) and 5f3-cholestane-3a,7a,26-triol (V) , which are the respective first putative precursors in the oxidation of the sterol side chain to a carboxylic acid in the formation of cholic acid and chenodeoxycholic acid (1) (Figs. 1 and 2) . As a consequence, these investigators (9, 10) believe that absent mitochondrial 26- hydroxylase activity is the inherited enzymatic abnormality in CTX, responsible for deficient primary bile acid synthesis. However, a different explanation for the defect in side-chain oxidation in bile acid synthesis in this disease has been proposed by Salen and co-workers (11, 12) . These workers suggested that side-chain cleavage in cholic acid synthesis occurs mainly via precursors hydroxylated at C-25 (Fig. 2) Figure 1 . Cholic acid and chenodeoxycholic biosynthetic pathway. Cholesterol (I) is transformed to 7a-hydroxycholesterol (II), which is converted to 7a-hydroxy-4-cholesten-3-one (III) by microsomal enzymes that are intermediates common to both pathways. In chenodeoxycholic acid synthesis, 7a-hydroxy-4-cholesten-3-one (III) is reduced to 5ft-cholestane-3a,7a-diol (IV) by cytosolic enzymes, which is then converted to 5j3-cholestane-3a,7a,26-triol (V) by mitochondria. The latter intermediate (V) is then transformed to chenodeoxycholic acid (VI) and propionic acid (VII). In cholic acid biosynthesis, 7a-hydroxy-4-cholesten-3-one (III) is 12a-hydroxylated by microsomal enzymes to yield 7a, 12a-dihydroxy-4-cholesten-3-one (VIII), which is reduced to 5#-cholestane-3a,7a,12a-triol (IX) by cytosolic enzymes. The latter compound is transformed to cholic acid (X) via the pathways illustrated in Fig. 2 .
to form 5/3-cholestane-3a,7a, 12a,24S,25-pentol (XV). As a result of this enzymatic block, which they believe is the principal inherited abnormality in CTX, cholic acid synthesis is impaired and precursors that are proximal to the defect and their metabolites then accumulate. The Mitochondrial 26-hydroxylase activity. Transformation of 5#-cholestane-3a,7a,12a-triol and 5,-cholestane-3a,7a-diol into 5Sf-cholestane3a,7a,12a,26-tetrol and 5#-cholestane-3a,7a,26-triol was performed according to the method of Shefer et al. (20) . Briefly, the standard incubation mixture contained 85 mM phosphate buffer (pH 7.4), 1.7 mM MgCI2, 4 mM DL isocitrate, and 0.1 ml of the mitochondrial fraction that contained 0.5-1 mg protein in a final volume of 1.0 ml and was preincubated for 5 min at 37°C. The reaction was then initiated by the addition of 100 nmol of either [7#_-3HJ50-cholestane3a,7a,12a-triol or [7_-3HJ]5#-cholestane-3a,7a-diol in 15 ul acetone and incubated for an additional 15 min with gentle shaking in air. The reaction was stopped by the addition of 0.1 ml of I N HCO and the products and precursors extracted with ethyl acetate. The reaction products (5,-cholestane-3a,7a,12a,26-tetrol or 5#-cholestane-3a,7a,26-triol) were isolated by TLC on Silica Gel G plates as described above for the 25-hydroxylated products: 5,-cholestane-3a,7a,26-triol (Rf 0.62) and 5,-cholestane-3a,7a,l12a,26-tetrol (Rf 0.45). Enzyme activities were calculated in the same manner as the microsomal products.
Microsomal 12a-hydroxylase activity
The formation of 7a,12a-dihydroxy-4-cholesten-3-one from 7a-hydroxy-4-cholesten-3-one by hepatic microsomes was assayed by the method of Nicolau et al. (22) .
[7#_3H]7a-Hydroxy4-cholesten-3-one (100 nmol) was solubilized in 50 ul acetone and preincubated at room temperature for 10 min with 0.3 ml of a solution containing 0.6 mg bovine serum albumin. The standard assay system contained, in a volume of 2.2 ml, the following: solubilized substrate (100 nmol/0.3 ml), 0.5 ml of microsomal suspension, 1 determined by GLC, in seven controls and six CTX subjects. Although cholic acid was the major bile acid in all individuals, the proportion of chenodeoxycholic acid in the bile of control subjects nearly equaled that of cholic acid. However, in the CTX subjects, the amount of cholic acid was two to three times higher than that of chenodeoxycholic acid. Further, the CTX bile contained significant amounts of tetra-and pentahydroxylated C2rbile alcohol glucuronides. These compounds were not detected in normal bile. The major biliary bile alcohols in these subjects have been identified as 5kcholestane-3a,7a, 12a,25-tetrol, 5#-Cholestane-3a,7a, 12a,23R,25-pentol, and 5(8-cholestane-3a,7a, 12a,24R,25-pentol, and are excreted conjugated with glucuronic acid. Although small amounts of 5f#-cholestanetetrols hydroxylated at C22 and C23 were detected, no 5(B-cholestane-3a,7a, 12a-triol was present in bile of the CTX subjects. Also of interest, CTX bile contained reduced quantities of the secondary bile acids, deoxycholic acid, and lithocholic acid, which probably reflect decreased intestinal bacterial 7a-dehydroxylase activity. Bile acid pool sizes and production rates. In Table III , are listed the measurements of cholic acid and chenodeoxycholic acid pool sizes and production rates in three CTX and seven control subjects as determined by the isotope dilution technique according to Lindstedt (13) . Mean cholic acid pool size was surements of 5f3-cholestane-3a,7a, 12a-triol-25-hydroxylase activity and 5,3-cholestane-3a,7a,12a-triol-26-hydroxylase activity were carried out in microsomes and mitochondria isolated from five control and seven CTX liver specimens.
Active 25-hydroxylation of 51-cholestane-3a,7a, 12a-triol was demonstrated in hepatic microsomes isolated from all control and CTX subjects (Table IV) . The mean activity in the CTX preparations was -20% higher than in the control subjects, but the difference was not statistically significant. No microsomal 26-hydroxylase activity was detected.
53-Cholestane-3a,7a,12a-triol-26-hydroxylase activity was demonstrated in all mitochondrial preparations, but the activity in CTX liver was sevenfold lower than in controls. Of importance, microsomal 25-hydroxylation of 5f3-cholestane3a,7a,12a-triol was almost three times greater than the corresponding mitochondrial 26- mitochondrial 26-hydroxylation in both control and CTX subjects. However, despite the presence of mitochondrial 5(3-cholestane-3a,7a,12a-triol-26-hydroxylase activity in all hepatic specimens, significantly higher activity was found in the control subjects than in the CTX patients. Chenodeoxycholic acid biosynthesis: hydroxylations at C-25 and C-26 by hepatic microsomal and mitochondrial preparations. According to current views, mitochondrial 26-hydroxylation of 5f3-cholestane-3a,7a-diol is the key reaction in the cleavage of the cholesterol side chain in chenodeoxycholic acid synthesis. To examine this reaction, we incubated hepatic mitochondria from five control and five CTX subjects individually with [7(_-3HH5(3-cholestane-3a,7a-diol under optimal conditions. The rate of formation of 5f3-cholestane-3a,7a,26-triol was determined and reported in Table V . 5(3-Cholestane3a,7a-diol-26-hydroxylase activity was demonstrated in every mitochondrial preparation from both control and CTX livers. However, the mean activity in the controls was twice that found for the CTX preparations. No 25-hydroxylase activity was detected in the mitochondria.
The corresponding formation of 5f3-cholestane-3a,7a,25-triol from 5(3-cholestane-3a,7a-diol by hepatic microsomes from control and CTX subjects was measured and also reported in Table V Microsomal 7a-hydroxy-4-cholesten-3-one-J2a-hydroxylase activity. Because the formation of chenodeoxycholic acid may be controlled by the amount of precursor diverted into the cholic acid synthetic pathway (12a-hydroxylation), measurements of 7a-hydroxy-4-cholesten-3-one-12a-hydroxylase activity were made in hepatic microsomes and mitochondria isolated from two control and two CTX subjects. The results are presented in Table VI . In control incubations, average micro- somal 7a-hydroxy-4-cholesten-3-one-12a-hydroxylase activity was more than three times lower than the average value found for CTX microsomal preparations. This finding indicates that microsomal 12a-hydroxylation is more active in CTX than control liver. Mitochondrial 12a-hydroxylase activity was not detected in either control or CTX preparations.
Discussion
The results of the present investigation confirm and extend our knowledge regarding the nature of the bile acid synthetic defect in CTX. They conclusively establish the abnormality of biliary bile acid composition in CTX with very low amounts of chenodeoxycholic acid, reduced levels of the secondary bile acids, and the excretion of large quantities of C-12 and C-25 hydroxylated bile alcohols conjugated with glucuronic acid. All of these findings are compatible with a block in bile acid synthesis; we have suggested previously that such a defect involves the incomplete oxidation of the cholesterol side chain (4). This premise is supported by the measurements of primary bile acid pool sizes and production rates reported in Table III . In CTX, mean cholic acid synthesis was reduced by 50%, while chenodeoxycholic acid production was even lower and amounted to only 14% of control values. Although the cholic acid pool was expanded modestly, chenodeoxycholic acid pool size was reduced markedly: 1.1±0.9 mg/kg in CTX subjects as compared with 9.3±1.2 mg/kg in the control subjects. We have suggested previously that many of the clinical and biochemical manifestations in CTX may be related to the extreme deficiency of chenodeoxycholic acid in the enterohepatic circulation and can be corrected by replacement therapy (7, 23, 24) . With regard to the mechanism of reduced chenodeoxycholic acid formation in CTX, it should be noted that the 26-hydroxylation pathway has been suggested to be dominant in side-chain oxidation in the biosynthesis of chenodeoxycholic acid in humans (Fig. 1) . The importance of this pathway is supported by the results in Table V , which demonstrate that mitochondrial 5(B-cholestane-3a,7a-diol-26-hydroxylase activity was 30 times more active than the corresponding microsomal 5B-cholestane-3a,7a-diol-25-hydroxylase activity. Similar levels of mitochondrial 26-hydroxylase activity and microsomal 25-hydroxylase activity for 5jB-cholestane-3a,7a-diol also have been reported previously for human liver by Bjorkhem et al. (25) . Thus, 25-hydroxylation is unlikely to contribute quantitatively to side-chain oxidation in chenodeoxycholic acid synthesis. Recently, Oftebro et al. (10) have suggested that defective chenodeoxycholic acid synthesis in CTX may result from the total absence of mitochondrial 26-hydroxylase activity, basing this conclusion on the fact that no activity was detected in a liver specimen from a single CTX subject. Further, these investigators administered tracer doses of 5#-cholestane-3a,7a-diol and 5,8-cholestane-3a,7a,26-triol intravenously and found that cholestanediol was poorly transformed, while the 26-hydroxylated cholestanetriol was efficiently converted into chenodeoxycholic acid (26) . The combination of these findings led them to conclude that deficient mitochondrial 26-hydroxylation was the primary bile acid synthetic defect in CTX (27) . However, the results of the present investigation suggest that mitochondrial 26-hydroxylation may not be rate-limiting and other factors may contribute substantially to the deficiency of chenodeoxycholic acid in the enterohepatic pool in CTX. Although chenodeoxycholic acid formation was 14% and pool size only 7% as large as controls, 5#-cholestane-3a,7a-diol-26-hydroxylase activity was present in all five CTX mitochondrial preparations. The mean activity of the mitochondrial 26-hydroxylase was '50% lower than in controls, but still should have provided sufficient 5#l-cholestane-3a,7a,26-triol for conversion into chenodeoxycholic acid so that the production rates and pool sizes ought to have been larger in the CTX subjects. However, the disproportionately small sizes of the pool and production rate suggest a diversion of precursors away from the chenodeoxycholic acid synthetic pathway. Our results support this contention by demonstrating that 7a-hydroxy-4-cholesten-3-one-12a-hydroxylase activity in CTX liver microsomes was threefold higher than in control liver microsomes (Table VI) . Because of increased 12a-hydroxylation, precursors are shunted into the cholic acid biosynthetic pathway, which would accentuate the deficiency of chenodeoxycholic acid and expand the cholic acid pool that was seen in Table III . Further, although 12a-hydroxylation of 7a-hydroxy-4-cholesten-3-one is presumably the favored reaction (25) , subsequent 12a-hydroxylation of 5#-cholestane-3a,7a,26-triol may also occur, which in turn further favors cholic acid formation. Indeed, we have demonstrated that 5#-cholestane3a,7a,26-triol can be converted in vivo into cholic acid in both CTX and control subjects (27) . However, in normal subjects in which 12a-hydroxylase activity is low, 5fl-cholestane3a,7a,26-triol was preferentially converted into chenodeoxycholic acid (27) . Thus, 26-hydroxylation of 5#-cholestane3a,7a-diol does not necessarily commit the precursor 5,-cholestane-3a,7a,26-triol to chenodeoxycholic acid, and thus its formation is not rate-limiting for chenodeoxycholic acid synthesis. Further, despite reduced 26-hydroxylation, chenodeoxycholic acid precursors do not accumulate in CTX. In other words, 12a-hydroxylation either occurring before or after side-chain hydroxylation is probably the major factor determining the formation of chenodeoxycholic acid. Thus, the profound deficiency in chenodeoxycholic acid synthesis and pool size in CTX reflects the diversion of precursors (hyperactive 12a-hydroxylation) into cholic acid pathway in combination with reduced mitochondrial 26-hydroxylation.
As concerns side-chain oxidation in cholic acid biosynthesis, both the 25-and 26-hydroxylation reaction mechanisms are presented in Fig. 2 (25) . Further, there is plentiful formation of 25-hydroxylated bile alcohols in CTX as evidenced by the combined daily urinary and fecal excretion of over 500 mg/d of 25-hydroxylated cholestanetetrols and cholestanepentols (7, 32) . Tius, almost 1 g of cholic acid or 25-hydroxylated bile alcohols are produced in CTX. We have demonstrated previously that in CTX there is a deficiency of the microsomal enzyme that stereospecifically 24S hydroxylates 5(3-cholestane-3a,7a, 12a,25-tetrol. This enzymatic reaction (Fig.  2 ) follows 25-hydroxylation and transforms 5,B-cholestane3a,7a, 12a,25-tetrol (XIV) into 5#-cholestane-3a,7a, 12a,-24S,25-pentol (XV) and in CTX liver was fourfold less active than control (12) . As a result of deficient 24S hydroxylase activity the proximal precursor, 5fl-cholestane-3a,7a, 12a,25-tetrol accumulates and is either glucuronidated and excreted in the bile or is further transformed by microsomal hydroxylations at C-22, C-23, or C24R into 5,B-cholestanepentols (7, 32) . Further, the results of the present investigation (active 25- hydroxylation combined with inactive 26-hydroxylation) confirm that side-chain oxidation in cholic acid formation in CTX occurs via the 25-hydroxylation pathway. This fact is consistent with our earlier study that demonstrated a precursor-product relationship between 5f3-cholestane-3a,7a, 12a,25-tetrol and cholic a4id in CTX (11) . However, right now we cannot conclude that this is the sole bile acid synthetic defect in the cholic acid pathway in CTX because 26-hydroxylation of 5,Bcholestane 3a,7a, 12a-triol by hepatic mitochondria was extremely low (Table IV) , as noted previously by Oftebro et al. (9) . Thus, it is not possible to define the enzymatic defect in cholic acid synthesis in CTX with certainty until the quantitative mechanism for side-chain cleavage in cholic acid synthesis is known.
In summary, certain generalizations about side-chain cleavage in bile acid synthesis may be derived from these studies. First, side-chain oxidation in chenodeoxycholic acid synthesis 
